Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immune Response of cAd3-EBO-S and cAd3-Marburg Vaccines in Healthy Adults
NCT04723602Phase 1Completed
- Sponsor
- Sabin Vaccine Institute
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of cAd3-EBO S and ChAd3-MARV in Ebola virus disease (EVD) and Marburg virus disease (MVD) (2 arms), sponsored by Sabin Vaccine Institute. Primary endpoints: Safety of Ebola and Marburg vaccines assessed by clinical observation at 7 days, Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Complete Blood Count (CBC) at 6 months and 4 more. Started Jan 2021; status: completed.
02
Drugs
cAd3-EBO SChAd3-MARV
03
Conditions
Ebola virus disease (EVD)Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT04723602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723602.